The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

Bavarian Nordic said on Thursday its mpox vaccine was approved by the EU's drug regulator for use in adolescents, bolstering the case for using the shot in the 12 to 17 age group to contain an ...

Bavarian Nordic’s Mpox vaccine met with the World Health Organization's approval on Monday for use among adolescents aged between 12-17. This age bracket is considered to be highly vulnerable to ...

Children, adolescents and those with weakened immune systems have been particularly vulnerable to mpox, a viral infection that typically causes flu-like symptoms and skin lesions filled with pus.

The World Health Organisation said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

The European Union’s drug regulator has approved Bavarian Nordic's mpox vaccine for use in adolescents aged 12 to 17, expanding its availability amid the ongoing outbreak in parts of Africa ...

The European Medicines Agency (EMA) has approved the use of Bavarian Nordic’s mpox vaccine in adolescents, increasing the chances for its use in this age group in Africa.

Children, adolescents and those with weakened immune systems have been particularly vulnerable to mpox, a viral infection that typically causes flu-like symptoms and skin lesions filled with pus.

WHO approves Bavarian Nordic's Jynneos vaccine for adolescents aged 12-17 to combat global mpox outbreak.